HPβCD’s Promise in Treating Ischemic Stroke
Ischemic stroke is a leading cause of mortality and long-term disability worldwide, with limited pharmacological interventions available. 2-hydroxypropyl-β-cyclodextrin (HPβCD), a
HPβCD’s Promise in Treating Ischemic Stroke
Ischemic stroke is a leading cause of mortality and long-term disability worldwide, with limited pharmacological interventions available. 2-hydroxypropyl-β-cyclodextrin (HPβCD), a
Surface-Engineered Amino-Graphene Oxide Aerogel Functionalized with Cyclodextrin for Desulfurization and Denitrogenation in Oil Refining
The selective removal of trace heteroatomic contaminants from fuel remains a critical challenge for clean combustion and refinery upgrading, particularly
Cyclodextrin and KR12-Lipopeptide Interactions
Natural antimicrobial peptides are a promising new class of antibiotics that offer a potential response to the growing challenge of
Comparative study of thiolated and alkenylated functionalized β-CDs as highly mucopenetrating and mucoadhesive drug delivery systems.
Oral drug delivery is a vital route because it is easy to administer, which improves patient compliance and allows for
Phosphorylated Beta-cyclodextrin as a New Bone-Targeting Drug Delivery System Could Change the Treatment of Osteoporosis and Other Bone Diseases
Researchers in Japan have developed a promising new drug delivery platform that not only carries medicines directly to bone, but
Arthur Lütringhaus, Godfather of catenanes was born 120 years ago
Professor Arthur Lütringhaus is the pioneer of the chemistry of interlocked supramolecular systems, that he named catenates. Arthur Lüttringhaus (1906-1992)
Potential Glioblastoma Therapy with Cationic Cyclodextrin Polymers as Drug Delivery Excipients
Glioblastoma (GB) is the most common and aggressive malignant brain tumor, with a median survival of only 12–15 months despite
Recent papers on Cyclodextrins in Nature
In Scientific Reports, a Japanese team investigated these effects for α-CD derivatives with various replaced substituents from the perspective of
Cantrixil: Advancing a Molecule’s Career with a Cyclodextrin Carrier
The success story of Cantrixil, a potent anti-cancer drug candidate, has been followed on our blog for years, and now
Oculis: eye drops with Dexamethasone/gamma-CD complex Phase 3 study concluded soon
Oculis’s most advanced product candidate, OCS-01, is currently in Phase 3 development and aims to be the first eye drop